H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $16 from $20 and keeps a Buy rating on the shares following the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics: Promising Pipeline and Strategic Developments Drive Buy Rating
- Aclaris Therapeutics Reports Q1 2025 Financial Results
- Aclaris Therapeutics price target lowered to $9 from $15 at Scotiabank
- Aclaris Therapeutics reports Q1 EPS (12c), consensus (12c)
- Aclaris Therapeutics appoints Hall as Chief Medical Officer